Exclusive

Publication

Byline

Singapore Clinical Trial: A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab ... Read More


Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus

Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Re... Read More


Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Re... Read More


Singapore Clinical Trial: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination W... Read More


Singapore Clinical Trial: A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors

Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugat... Read More


Singapore Clinical Trial: A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY® Kids)

Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the p... Read More


Perak to review need for supplementary budget amid West Asia tensions

IPOH, April 15 -- Perak Menteri Besar Datuk Seri Saarani Mohamad said the state government will study whether there is a need to table a supplementary budget following concerns over the escalating Wes... Read More


Continental Controls postpones board meeting

Mumbai, April 15 -- Continental Controls has postponed the meeting of the Board of Directors which was scheduled to be held on 13 April 2026. The meeting will now be held on 15 April 2026. Published ... Read More


Clinical Trial: HIFEM in Pospartum (High Intensity Focused Electro-Magnetic Technology)

U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07528560) titled 'HIFEM in Pospartum (High Intensity Focused Electro-Magnetic Technology)' on March 26. Bri... Read More


Clinical Trial: Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07529951) titled 'Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers' on April 08. Brie... Read More